Clinical NewsMRIBusyMay 10, 2022Latest in MRIISMRM: Contrast-free MR angiography comparable to CT for PE detectionMay 10, 2025ISMRM: Insulin resistance in women associated with less myelin, changes in brainMay 10, 2025SponsoredEchelon Synergy 1.5T MRI with MotionClear Comprehensive Motion Correction SuiteJanuary 1, 2025ISMRM: Switching between full and short breast MRI reduces recallsMay 10, 2025Related StoriesMRIMRI can help guide women's treatment decisions for DCISMRIVideo from ISMRM 2022: Tim Leiner on his move to Mayo ClinicMRIVideo from ISMRM 2022: Why Nandita deSouza loves the congressSponsor ContentEchelon Synergy 1.5T MRI with MotionClear Comprehensive Motion Correction Suite
.fFmgij6Hin.png?auto=compress%2Cformat&fit=crop&h=100&q=70&w=100)
.fFmgij6Hin.png?auto=compress%2Cformat&fit=crop&h=167&q=70&w=250)
![Images depict axial MRI scans in a 50-year-old premenopausal female patient with biopsy-proven 12-mm invasive lobular cancer in the lower outer quadrant of the left breast. Upper images are subtracted dynamic contrast-enhanced (DCE) MRI scans from the first and second postcontrast acquisitions. Lower images are ultrafast MRI scans obtained within 24 hours after the DCE study (four consecutive subtracted dynamic frames from time points [T] 6–9). There is marked background parenchymal enhancement (BPE) on the DCE MRI scans. Thus, the known cancer (arrow) is barely visible; it exhibits only slightly stronger enhancement than the normal fibroglandular tissue, which results in low conspicuity. At ultrafast MRI there is less BPE, and still the cancer is barely visible because it starts to enhance simultaneously with the BPE. The conspicuity of the cancer is even reduced compared with the DCE series. Both of the readers missed this cancer on both the DCE and ultrafast MRI scans.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2025/05/2025-05-06-rsna-ultrafast-dce-mri-breast.Gzvq76udFr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
